We are live on ! Find out more
NTGN

Neon Therapeutics, Inc. Common Stock
NTGN

Delisted

NTGN was delisted on the 5th of May, 2020.

Back to rankings

41 hedge funds and large institutions have $233M invested in Neon Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 41 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
41
Holders Change
+41
Holders Change %
–
% of All Funds
0.94%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
41
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TGI
TRV GP III
Massachusetts
+$133M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$32.7M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$31.3M
4
PHS
PFM Health Sciences
California
+$13.3M
5
HIM
Hillhouse Investment Management
Cayman Islands
+$9.75M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
TGI
1
TRV GP III
Massachusetts
$123M +$133M +9,741,636 New
Wellington Management Group
2
Wellington Management Group
Massachusetts
$30M +$32.7M +2,386,559 New
Fidelity Investments
3
Fidelity Investments
Massachusetts
$26.7M +$31.3M +2,286,471 New
PHS
4
PFM Health Sciences
California
$10.8M +$13.3M +974,761 New
HIM
5
Hillhouse Investment Management
Cayman Islands
$8.97M +$9.75M +711,809 New
HMC
6
Harvard Management Company
Massachusetts
$6.37M +$6.93M +505,871 New
ACH
7
ArrowMark Colorado Holdings
Colorado
$5.07M +$5.51M +402,210 New
CC
8
Casdin Capital
New York
$4.26M +$4.63M +338,345 New
Millennium Management
9
Millennium Management
New York
$2.02M +$2.2M +160,507 New
PC
10
PointState Capital
New York
$1.89M +$2.05M +150,000 New
MIM
11
Monashee Investment Management
Massachusetts
$1.57M – – –
Alyeska Investment Group
12
Alyeska Investment Group
Illinois
$1.57M +$1.71M +125,000 New
LCM
13
Laurion Capital Management
New York
$1.57M +$1.71M +125,000 New
Citadel Advisors
14
Citadel Advisors
Florida
$1.47M +$1.59M +116,418 New
Norges Bank
15
Norges Bank
Norway
$945K +$1.03M +75,000 New
WMSA
16
Weiss Multi-Strategy Advisers
New York
$907K +$986K +71,981 New
Goldman Sachs
17
Goldman Sachs
New York
$788K +$856K +62,500 New
Vanguard Group
18
Vanguard Group
Pennsylvania
$788K +$856K +62,500 New
JP Morgan Chase
19
JP Morgan Chase
New York
$708K +$770K +56,200 New
DCM
20
DAFNA Capital Management
California
$630K +$685K +50,000 New
USAA
21
United Services Automobile Association
Texas
$607K +$659K +48,144 New
MWNA
22
Marshall Wace North America
New York
$530K +$576K +42,100 New
DIM
23
DC Investments Management
Virginia
$504K +$548K +40,000 New
MCP
24
Maso Capital Partners
Hong Kong
$441K +$479K +35,000 New
PPA
25
Parametric Portfolio Associates
Washington
$328K +$356K +26,000 New
1
2

NTGN Hedge Fund Activity: Q2 2018 in Review

41 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Neon Therapeutics, Inc. Common Stock (NTGN) for Q2 2018, worth a combined $233M.

Buyers outnumbered sellers: 41 funds opened new NTGN positions and 0 closed out — a net gain of 41 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was TRV GP III, opening a new position worth an estimated $133M.

  • 41 institutional investors held Neon Therapeutics, Inc. Common Stock (NTGN) as of Q2 2018, up from 0 in Q1 2018.
  • Funds reported $233M of Neon Therapeutics, Inc. Common Stock stock for Q2 2018.
  • 41 funds opened new Neon Therapeutics, Inc. Common Stock positions in Q2 2018 and 0 closed out, a net change of +41 holders.
  • The largest Neon Therapeutics, Inc. Common Stock buyer in Q2 2018 was TRV GP III, an estimated $133M added.

Based on aggregated 13F filings for Q2 2018.